奥美拉唑在肝硬化患者中的药动学研究  

Pharmacokinetics of omeprazole in patients with liver cirrhosis

作　　者：刘丽萍[1] 魏振满[1] 贺承山[1] 孙效东[2] 李永纲 唐卫红[4] 

机构地区：[1]解放军302医院药学部,北京100039 [2]解放军总医院药理室,北京100850 [3]302医院一科 [4]北京职工医学院

出　　处：《中国药学杂志》2001年第4期259-261,共3页Chinese Pharmaceutical Journal

摘　　要：目的　研究 8例肝硬化患者静脉滴注奥美拉唑 (OME)的药动学特性。方法　采用HPLC测定血浆OME浓度 ,以 3P97程序计算药动学参数。结果　肝硬化患者静滴OME的血药浓度曲线符合二室模型 ,消除半衰期为 ( 3.34± 0 .38)h ,明显大于国内外文献报道的健康人结果 ,药物清除明显减慢。OBJECTIVE: To study the pharmacokinetics of omeprazole (OME) in 8 patients with liver cirrhosis. METHODS: The plasma concentrations of OME were determined by HPLC, and the pharmacokinetic parameters were computed by using 3P97 program. RESULTS: The plasma concentration versus time curve following intravenous 40 mg OME in patients with liver cirrhosis was coincident with two-compartment model. The elimination half-life was (3.34 ± 0.38) h, which was longer than the value of the healthy volunteers and CLs was lower than the value of the healthy volunteers. CONCLUSION: The dosage of OME may be given in the half of the routine dosage or adjusted conditionally when using for the patients with liver cirrhosis.

关 键 词：奥美拉唑 药动学 肝硬化 

分 类 号：R575.205[医药卫生—消化系统] R975[医药卫生—内科学]